summary Osteoarthritis (OA), the most common joint disorder, is a disease involving all the articular structures. It presents both degenerative and inflammatory aspects. Recently, the important role of Bradykinin (BK), a phlogistic mediator, has been proposed in the pathophysiology of OA. In our review, we summarized the currently available information on the mechanisms of action of BK in OA by linking its B 2 receptors. Then, we analyzed the data about the effects of BK in synoviocytes and chondrocytes cultures. Furthermore, we described the action of B 2 receptor antagonists (Icatibant and Fasitibant), presenting them as new promising symptom-anddisease-modifying agents in the treatment of OA. However, more in vitro, animal model and clinical studies, are needed to better understand the mechanisms of action as well as the efficacy and tolerability of the B 2 receptor antagonists in OA.
n INTRODUCTION O steoarthritis (OA) is the most prevalent disease of articular joints in older adults in industrialized countries (1) . The number of people with symptomatic OA is likely to increase due to the aging of the population. This disease plays an important medical and social role, causing deformity and joint disability, especially when it affects the knee and hip (2) . The main features of OA are degeneration and loss of articular cartilage, but all the joint components, including the bone, synovial lining, ligaments, tendons and periarticular tissue undergo structural and functional alterations during the course of OA progression (3) . Cartilage breakdown is attributable to an imbalance between synthetic (anabolic) and resorptive (catabolic) activities of the resident chondrocytes. The catabolic processes exceed anabolic processes leading to a net decrease in extracellular matrix components (ECM) (type II collagen and proteoglicans) (3) (4) (5) (6) . Although the pathogenesis of OA is not fully understood, current knowledge indicates that many catabolic and proinflammatory factors contribute to the degradative cascade in OA. The spectrum of these factors includes different cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor a (TNF-a), chemokines such as interleukin-8 (IL-8), numerous metalloproteinases (MMP s ) (MMP-3 MMP-9 MMP-13), prostaglandin E 2 (PGE 2 ) and nitric oxide (NO) (5) . Recently, several evidences suggest the involvement of bradykinin (BK) and B 2 receptors in the pathophysiology of OA (7, 8) . The aim of this study is to summarize preclinical and clinical evidences, which supports the hypothesis for a role of BK in OA pathogenesis.
n BRADYKININ, KININS AND THEIR RECEPTORS
Kinins are peptides involved in both acute and chronic inflammation inducing pain, edema formation, vasodilation, and prostaglandins synthesis. They are produced by specific proteases such as plasma and tissue kallikrein. Kallikrein-kinin system is activated by coagulation factor XII, a self-activating protease that converts prekallikrein in kallikrein. Kallicrein, in turn, activates the coagulation factor XII causing a positive feedback. Two different cascades and specific pre- cursors produce kinins: one in the plasma, the high molecular weight kininogen, and another in the tissues, the low molecular weight kininogen (9) (Fig. 1) . The high molecular weight kininogen generates, by plasma kallikrein, BK, a nonapeptide whose aminoacid sequences is Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg, whereas low molecular weight kininogen leads to the formation of kallidin (Lys-BK), having amino-terminal additional lysine residual. BK and Lys-BK are rapidly degraded by different enzymes, such as the carboxypeptidase M and N, which cleave off the carboxy-terminal arginine to produce the active desArg metabolites (9, 10) ( Fig. 1 (18) quantified BK levels in knee synovial fluids of patients with gonarthrosis, finding the basal BK content ranging between 281 and 563 pg/ mL (mean 422) and generated BK content ranging 2591-4264 pg/mL (mean 3427). Moreover, a significant positive correlation was found between BK levels, both the basal and generated ones, and the contents of IL-6, one of the most important cytokines involving in OA.
n BRADIKININ AND B 2 
RECEPTORS IN HYPERALGESIA AND INFLAMMATION
The algogenic and proinflammatory activity of BK is linked to the activation and sensitization of nociceptive afferent nerve (19) . BK, through B 2 receptor interaction, activates the phospholipase C (PLC) with consequent inositol phosphate (IP) hydrolysis and diacylglycerol (DAG) production, which in turn potentiates the activation and increases the expression of vanilloid TRPV1 receptors (19) (20) (21) (22) (23) (24) (25) . BK has also been shown to evoke calcitonin gene related peptide (CGRP) release in knee joints of mice, which spontaneously developed OA, and to produce a significantly higher release of PGE 2 in joints of animals treated with collagenase as a model of OA (26) . In 1993, Gotoh et al. (27) showed that the intra-articular administration of BK could induce hyperalgesia in rats. Consecutive studies of Davis and Perkins (28, 29) demonstrated that the hyperalgesia, produced by intra-articular administration of substances such as capsaicin or substance P that stimulate the nociceptive sensory fibers, could be blocked by systemic treatment with Icatibant, a B 2 receptor antagonist (30) . The intra-articular injection of the synthetic peptide of BK into dog knee (500 μg in 1 mL) caused local warmth and swelling within a few minutes of administration, as a consequence of hyperemia of synovial membranes and increased synovial fluid demonstrating the involvement of BK in inflammatory events (14) . Later studies in the rat synovium demonstrated that intra-articular administration of BK induced plasma extravasation and neutrophils accumulation (31-33) more potently than other inflammatory mediators such as substance P, histamine, and CGRP (34) . BK-induced plasma extravasation resulted due to a direct stimulation of B 2 -type BK receptor, which is likely to be located on the vascular endothelial cells and/or smooth muscle and could be inhibited by the selective B 2 receptor antagonist (35) .
n KININS EFFECTS ON SYNOVIOCYTES
The synovial membrane presents in its superficial layer a unique cellular lining, the synovial intima, which is one of three cells In particular, the Authors focused on the ability of BK to induce IL-6 and IL-8 production by synoviocytes and the mechanism involved. They showed that BK, after a long-term incubation, was able to increase the release of IL-6 and IL-8 from human synoviocytes in a concentration-dependent manner. Furthermore, the Authors presented pharmacological evidence that PLC and nuclear factor kappaB (NF-κB) activations were involved in the BK-mediated release of IL-8, as previously described for IL-6 in other studies. and IL-8, an effect which was neutralized by MEN16132, but not by the antagonist of the receptor B 1 . Furthermore, the Authors investigated the mechanisms involved in the IL-6 and IL-8 release induced by BK in human chondrocytes by pre-treating these cells with different inhibitors. Human chondrocytes were exposed to pretreatment with the nonselective COX inhibitor indomethacin, the nonselective lipoxygenase nordihydroguaiaretic acid (NDGA), or the glucocorticoid dexamethasone before BK stimulation. The release of IL-6 induced by BK was partially inhibited by indomethacin and NDGA, but it was not the same for the release of IL-8. Dexamethasone has been shown to reduce both the release of IL-6 and IL-8 stimulated by BK.
In conclusion, this study demonstrated the important role of BK in inflammatory and degenerative process of OA and advanced the hypothesis of a possible use of BK B 2 receptor antagonists in the treatment of OA.
n BRADIKININ B 2 RECEPTOR ANTAGONISTS AND THEIR CLINICAL IMPLICATIONS
Considering the important role of BK in inflammation and its activity on different kinds of joint cells, B 2 receptor antagonists may represent a new therapeutic strategy in OA (45) . Icatibant is a synthetic decapeptide and a potent, stable, specific, and longacting antagonist of the BK B 2 receptor; it is currently used for angioedema attacks (46, 47) (Fig. 2) . Over the years, much of the pharmaceutical research was aimed at the identification of nonpeptidic small molecules, which are more useful from a clinical point of view (48) (49) (50) . These studies led to the synthesis of a nonpeptide B 2 receptor antagonist, known as MEN16132 or Fasitibant (Fig.  2) . Different studies were conducted to investigate the pharmacological characterization (affinity, selectivity, and antagonist potency) of MEN16132 in various animal and human tissues (i.e. mouse lung and 
